2026-09-09Screening report
Data as of 2026-09-09US market
Summary
September 9, 2026 screening identifies extreme valuation dislocations in DexCom, Amgen, Pinterest, Expedia, and Salesforce.
Screening weights
Fundamental improvement25%
Candidate comparison
| Rank | Ticker | Sector | 3M return | Revenue YoY | OPM Δ | FCF | Score |
|---|
| 1 | DexCom | Healthcare | -21.2% | +15.3% | +1.8%p | Positive | 8.9 |
| 2 | Amgen | Healthcare | -6.8% | +10.0% | +1.2%p | Positive | 8.7 |
| 3 | Pinterest | Communication | -14.5% | +21.0% | +3.4%p | Positive | 8.5 |
| 4 | Expedia | Consumer | -8.9% | +6.2% | +1.5%p | Positive | 8.4 |
| 5 | Salesforce | Technology | -7.1% | +8.4% | +2.4%p | Positive | 8.3 |
| 6 | Lululemon | Consumer | -14.8% | +9.8% | +0.8%p | Positive | 8.1 |
| 7 | Gartner | Technology | -9.4% | +6.8% | +1.1%p | Positive | 7.9 |
| 8 | Snowflake | Technology | -12.8% | +29.1% | +3.2%p | Positive | 7.8 |
| 9 | PayPal | Financials | -5.2% | +7.2% | +1.4%p | Positive | 7.7 |
| 10 | Stryker | Healthcare | -8.2% | +9.5% | +0.9%p | Positive | 7.5 |
Screened names (observations)
Observation
RSI under 28 on temporary pharmacy rebate mix noise; core revenue expanded +15.3% YoY with
Catalysts to watch
- Stelo OTC biosensor retail volume expansion
- Commercial payer coverage for non-insulin Type 2 diabetics
Risks
- Rebate structure pressure in US pharmacy channels
Framework exit signals
- G7 sensor volume growth drops below +10% YoY
Metrics to watch
- G7 sensor volume growth
- Stelo OTC adoption rate
Observation
Steepest 1-day decline (-10.1%) since Oct 2000 on competitor trial noise; trading at attractive
Catalysts to watch
- MariTide Phase 2 obesity data readouts
- Double-digit volume growth in Repatha and Tezspire
Risks
- GLP-1 obesity trial disclosures by competitors
Framework exit signals
- MariTide development safety discontinuation
Metrics to watch
- MariTide Phase 2 trial updates
- Core product volume growth
Observation
Oversold -7.6% drop on CFO departure; fundamentals accelerating with +21% YoY revenue grow
Catalysts to watch
- Performance+ AI ad campaign adoption
- Amazon and Google third-party ad monetization
Risks
- CFO leadership transition friction
Framework exit signals
- Global MAUs turning negative QoQ
Metrics to watch
- Global MAU growth
- International ARPU
Observation
Crude oil hitting $100 triggered indiscriminate travel sell-off; trading at ~11x forward P/E
Catalysts to watch
- B2B enterprise travel platform partnerships
- One Key loyalty program repeat booking gains
Risks
- Sustained jet fuel price surge dampening travel
Framework exit signals
- Gross bookings growth below +2.0% YoY
Metrics to watch
- B2B gross bookings
- Lodging room nights growth
Observation
Enterprise SaaS multiple compression offers prime entry; produces 32.5% OPM (+2.4%p) and $1
Catalysts to watch
- Dreamforce 2026 Agentforce general availability
- Autonomous enterprise AI agent consumption contracts
Risks
- Enterprise software procurement delays
Framework exit signals
- cRPO growth dipping below +6.0% YoY
Metrics to watch
- cRPO constant-currency growth
- Agentforce customer conversion
AlphaSignal: Top 5 Oversold US Stocks Poised for Rebound
1. Executive Summary
- Date: September 9, 2026 | Market: US Equities (S&P 500 / Russell 1000)
- Overview: WTI crude past $100 triggered severe selling, creating acute oversold dislocations in quality compounders.
- Criteria: Daily drop / RSI < 30, expanding revenue & OPM, positive FCF.
2. Candidate Comparison Table
- DXCM (8.9) - Healthcare | 3M: -21.2% | Rev: +15.3% | OPM: +1.8%p | FCF: Pos
- AMGN (8.7) - Healthcare | 3M: -6.8% | Rev: +10.0% | OPM: +1.2%p | FCF: $10.5B
- PINS (8.5) - Comm | 3M: -14.5% | Rev: +21.0% | OPM: +3.4%p | FCF: $650M
- EXPE (8.4) - Consumer | 3M: -8.9% | Rev: +6.2% | OPM: +1.5%p | FCF: $2.1B
- CRM (8.3) - Tech | 3M: -7.1% | Rev: +8.4% | OPM: +2.4%p | FCF: $12.8B
- LULU (8.1) | 7. IT (7.9) | 8. SNOW (7.8) | 9. PYPL (7.7) | 10. SYK (7.5)
3. Final Top 5 Recommendations
- DXCM (DexCom): RSI < 28 on transitory rebate noise | +15.3% rev, expanding OPM | Stelo OTC launch.
- AMGN (Amgen): -10.1% plunge on competitor noise | $10.5B FCF, 3.1% dividend yield.
- PINS (Pinterest): -7.6% drop on CFO departure | +21% rev growth, $2.7B net cash.
- EXPE (Expedia): ~11x forward P/E | +20% B2B growth, $2.1B FCF.
- CRM (Salesforce): 32.5% OPM (+2.4%p) | $12.8B FCF | Dreamforce Agentforce launch.
4. Conclusion
- Highest Conviction: DXCM | Dislocation: AMGN | Growth: PINS | Value: EXPE | AI: CRM
Not investment advice. Scores and lists are relative snapshots.
← All notes